Pentraxin-3: possibilities and perspectives for using the biomarker in patients with previous COVID-19

Objective: to determine the potential prognostic value of serum biomarkers in relation to the development of adverse cardiovascular events in patients who have undergone COVID-19. Material and methods. The prospective study involved 114 patients hospitalized with confirmed COVID-19. In addition to standard examinations, blood samples were taken from patients on the day of hospitalization to determine the level of serum cardiovascular biomarkers, including pentaxin-3 (PTX3). The patients were monitored for 366 [365; 380] days after discharge from the COVID hospital with registration of major adverse cardiovascular events (MACE) developed in patients.